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A bs tr ac t
Background
Laparoscopic resection of colorectal cancer is widely used. However, robust evi-
dence to conclude that laparoscopic surgery and open surgery have similar out-
comes in rectal cancer is lacking. A trial was designed to compare 3-year rates of 
cancer recurrence in the pelvic or perineal area (locoregional recurrence) and sur-
vival after laparoscopic and open resection of rectal cancer.
Methods
In this international trial conducted in 30 hospitals, we randomly assigned patients 
with a solitary adenocarcinoma of the rectum within 15 cm of the anal verge, not 
invading adjacent tissues, and without distant metastases to undergo either laparo-
scopic or open surgery in a 2:1 ratio. The primary end point was locoregional recur-
rence 3 years after the index surgery. Secondary end points included disease-free 
and overall survival.
Results
A total of 1044 patients were included (699 in the laparoscopic-surgery group and 
345 in the open-surgery group). At 3 years, the locoregional recurrence rate was 
5.0% in the two groups (difference, 0 percentage points; 90% confidence interval 
[CI], −2.6 to 2.6). Disease-free survival rates were 74.8% in the laparoscopic-surgery 
group and 70.8% in the open-surgery group (difference, 4.0 percentage points; 95% 
CI, −1.9 to 9.9). Overall survival rates were 86.7% in the laparoscopic-surgery group 
and 83.6% in the open-surgery group (difference, 3.1 percentage points; 95% CI, 
−1.6 to 7.8).
Conclusions
Laparoscopic surgery in patients with rectal cancer was associated with rates of 
locoregional recurrence and disease-free and overall survival similar to those for 
open surgery. (Funded by Ethicon Endo-Surgery Europe and others; COLOR II 
ClinicalTrials.gov number, NCT00297791.)
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Colorectal cancer is the third most common cancer worldwide and accounts for nearly 1.4 million new cases and 
694,000 deaths per year. Approximately one third 
of all colorectal cancers are localized in the rec-
tum.1-4 Less than a half century ago, rectal can-
cer had a poor prognosis, with cancer recurrence 
rates in the pelvic or perineal area (locoregional 
recurrence) of up to 40% and 5-year survival 
rates after surgical resection of less than 50%.5,6 
In the 1980s, Heald and Ryall6 introduced a new 
surgical technique of complete removal of the 
fatty envelope surrounding the rectum (mesorec-
tum), called total mesorectal excision. The adop-
tion of total mesorectal excision combined with 
neoadjuvant chemoradiotherapy in selected pa-
tients has reduced locoregional recurrence rates 
to below 10% and improved cancer-free survival 
rates to more than 70%.7-10
Laparoscopic surgery has progressively replaced 
open colonic surgery in recent decades owing to 
favorable short-term outcomes, such as less pain, 
reduced blood loss, and improved recovery time.11 
Initially, there was concern regarding the safety 
of laparoscopic colectomy after reports of cancer 
recurrence in the abdominal wall.12,13 In various 
trials in which patients with colon cancer were 
randomly assigned to undergo either open or 
laparoscopic surgery, evidence was obtained that 
laparoscopic surgery was associated with similar 
disease-free and overall survival rates as open 
surgery.14,15 However, evidence is lacking from 
large, randomized clinical trials indicating that 
survival after laparoscopic resection of rectal 
cancer is not inferior to open surgery. We previ-
ously reported that laparoscopic surgery in pa-
tients with rectal cancer was associated with 
similar surgical safety and improved recovery 
time, as compared with open surgery.16 In the 
Colorectal Cancer Laparoscopic or Open Resec-
tion (COLOR) II trial, we report the long-term 
rates of locoregional recurrence and survival in 
patients who were randomly assigned to under-
go one of the two procedures.
Me thods
Study Design and Oversight
The COLOR II trial was a noninferiority, open-
label, multicenter trial conducted at 30 centers in 
8 countries. The study was designed by members 
of the protocol committee. The local investiga-
tors and the trial manager gathered the data. The 
authors analyzed the data and vouch for the ac-
curacy of the data and the analyses and the fidel-
ity of the study to the protocol (available with the 
full text of this article at NEJM.org). The authors 
wrote the manuscript and made the decision to 
submit the manuscript for publication. The sponsor 
of the study, Ethicon Endo-Surgery Europe (a sub-
sidiary of Johnson & Johnson), had no role in the 
study design, data gathering, analyses and inter-
pretation, or writing of the manuscript.
Patients
Patients with a solitary adenocarcinoma of the 
rectum within 15 cm from the anal verge without 
distant metastases who were candidates for elec-
tive surgery were eligible for inclusion. The local-
ization of the tumor was categorized as the upper 
rectum (distal border of tumor, 10 to 15 cm from 
the anal verge), middle rectum (5 to 10 cm from 
the anal verge), or lower rectum (<5 cm from the 
anal verge). Patients with T4 tumors or T3 tumors 
within 2 mm of the endopelvic fascia, as deter-
mined on computed tomography (CT) or mag-
netic resonance imaging (MRI), were excluded. 
Other exclusion criteria have been reported previ-
ously.16 The study was approved by the institu-
tional review board at each participating center. 
All patients provided written informed consent.
Randomization
Randomization was performed at the patient 
level. Laparoscopic and open surgery were per-
formed at all participating centers. Eligible pa-
tients were randomly assigned in a 2:1 ratio to 
undergo either laparoscopy or open surgery ac-
cording to a list of randomization numbers with 
treatment assignments. This list was computer-
generated, with stratification according to hospi-
tal, tumor location, and the presence or absence 
of preoperative radiotherapy. An Internet applica-
tion allowed central randomization.
Procedures and Quality Control
The use of neoadjuvant therapy was determined 
by multidisciplinary cancer boards at each par-
ticipating hospital, according to local standards, 
without differences between the laparoscopic-
surgery group and the open-surgery group. All 
procedures were required to comply with the 
principles of total mesorectal excision or partial 
mesorectal excision if the cancer was located in 
the upper part of the rectum.6
The selection of centers for participation in 
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the trial was based on stringent quality assess-
ment by the study management committee to 
confirm the use of proper surgical technique. 
Unedited recordings of five consecutive laparo-
scopic total mesorectal excisions were evaluated. 
The respective pathology reports of these five 
consecutive cases were reviewed to confirm 
completeness of the specimens. Pathologists 
adhered to standardized processing and assess-
ment of specimens, as described in detail in the 
trial protocol, to ensure accurate reporting by all 
participating centers.16 The circumferential re-
section margin was defined as “involved” when 
tumor cells were present within 2 mm from the 
lateral surface of the mesorectum.
End Points
The primary end point was locoregional recurrence 
3 years after the index surgery. Secondary end 
points included disease-free and overall survival.
Follow-up
Minimal required follow-up included annual clini-
cal examinations for 5 years after surgery. Three 
years after the index surgery, CT or MRI of the 
pelvis combined with imaging of the liver and 
the chest were performed. Recurrent disease was 
defined as the presence of locoregional recur-
rence, the presence of distant metastases, or 
death from rectal cancer.
Statistical Analysis
We used the Kaplan–Meier method to estimate 
the difference in recurrence rates between the 
two study groups at 3 years postoperatively. Lapa-
roscopic surgery was considered to be noninferior 
to open surgery if the one-sided 95% confidence 
interval for the difference in locoregional recur-
rence rates excluded an absolute difference of 5 per-
centage points or more. With 1000 patients who 
could be evaluated at a ratio of 2:1, the power of 
the noninferiority test was 80% at a locoregional 
recurrence rate of 10% in the open-surgery group.
All analyses were performed on an intention-
to-treat basis. We used the Kaplan–Meier method 
to compare rates of recurrence, disease-free sur-
vival, and overall survival at 3 years. The one-
sided 95% confidence interval for the between-
group difference in locoregional recurrence 
corresponds to the upper limit of the two-sided 
90% confidence interval for this difference. For 
survival rates, two-sided 95% confidence inter-
vals were calculated. In addition, we performed 
as-treated analyses for locoregional recurrence, 
disease-free survival, and overall survival.
R esult s
Patients
From January 2004 through May 2010, a total of 
1103 patients with rectal cancer underwent ran-
domization. Of these patients, 739 were assigned 
to undergo laparoscopic surgery and 364 to un-
dergo open surgery. After the exclusion of 59 pa-
tients following randomization, 1044 patients 
(699 in the laparoscopic-surgery group and 345 
patients in the open-surgery group) were includ-
ed in the analysis (Fig. 1). In total, 1036 patients 
were included in the long-term analyses.
At the 3-year follow-up, data were available 
for 771 patients (74%) regarding locoregional 
recurrence, 923 (89%) regarding disease-free 
survival, and 903 (87%) regarding overall sur-
vival. The clinical characteristics of the patients 
were similar in the two groups, as were the 
proportions of patients who received neoadju-
vant chemoradiotherapy (Table 1).
Short-Term Outcomes
Five patients who were randomly assigned to the 
open-surgery group underwent laparoscopic sur-
gery. Of these patients, three requested laparo-
scopic surgery after randomization, and the rea-
son for crossover was unknown for the other two 
patients. In addition, seven patients in the lapa-
roscopic-surgery group underwent open surgery: 
one owing to poor pulmonary condition, five 
because no laparoscopic surgeon was available, 
and one for an unknown reason. A total of 86% 
of laparoscopic and open procedures were per-
formed by surgeons who had performed both 
laparoscopic and open surgeries for rectal cancer. 
The conversion rate from laparoscopic surgery to 
open surgery was 16%. In the laparoscopic-surgery 
group, the operating time was 52 minutes longer, 
bowel function returned 1 day earlier, and the 
hospital stay was 1 day shorter than in the open-
surgery group. There were no significant differ-
ences in the rates of anastomotic leaking, com-
plication, or death.16
Pathological Analyses
There were no significant between-group differ-
ences for all lesions with respect to macroscopic 
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1103 Patients underwent randomization
739 Were assigned to undergo
laparoscopic surgery
364 Were assigned to undergo
open surgery
19 Were excluded
2 Had distant metastases
2 Did not have carcinoma
7 Had T4 tumor
7 Withdrew consent
1 Underwent emergency
operation
40 Were excluded
12 Had distant metastases
12 Did not have carcinoma
6 Had T4 tumor
2 Died before surgery
1 Withdrew consent
7 Had other reasons
699 Were included in the analysis
7 Underwent open surgery
345 Were included in the analysis
5 Underwent laparoscopic surgery
Figure 1. Enrollment and Outcomes.
completeness of the mesorectum, involved cir-
cumferential resection margins (Tables 1 and 2), 
or distal resection margins (median, 3.0 cm in 
the two groups).
Locoregional Recurrence
At 3 years, the rate of locoregional recurrence 
was 5.0% in each of the study groups (31 patients 
in the laparoscopic-surgery group and 15 in the 
open-surgery group) (Table 2). The upper limit of 
the 90% confidence interval for the absolute be-
tween-group difference in the rate of locoregion-
al recurrence (2.6 percentage points) was below 
the noninferiority margin of 5 percentage points. 
In the intention-to-treat analysis, rates of loco- 
regional recurrence of upper rectal cancers were 
3.5% in the laparoscopic-surgery group and 2.9% 
in the open-surgery group (difference, 0.6 per-
centage points; 90% CI, −2.9 to 4.1). In patients 
with middle rectal cancers, locoregional recur-
rence rates were 6.5% and 2.4%, respectively (dif-
ference, 4.1 percentage points; 90% CI, 0.7 to 7.5); 
in patients with lower rectal cancers, the rates 
were 4.4% and 11.7%, respectively (difference, 
−7.3 percentage points; 90% CI, −13.9 to −0.7).
In the as-treated analysis, the locoregional 
recurrence rates in patients with upper rectal 
cancers were 3.0% in the laparoscopic-surgery 
group and 3.9% in the open-surgery group (dif-
ference, −0.9 percentage points; 90% CI, −4.6 to 
2.8). In patients with middle rectal cancers, loco-
regional recurrence rates were 5.7% and 4.1%, 
respectively (difference, 1.6 percentage points; 
90% CI, −2.3 to 5.5); in patients with lower rec-
tal cancers, the rates were 3.8% and 12.7%, re-
spectively (difference −8.9 percentage points; 
90% CI, −15.6 to −2.2). Among 46 patients with 
locoregional recurrence at 3 years, 27 patients 
had distant metastases as well.
Disease-free and Overall Survival
At 3 years, the rate of disease-free survival was 
74.8% in the laparoscopic-surgery group and 
70.8% in the open-surgery group (difference, 4.0 
percentage points; 95% CI, −1.9 to 9.9) (Fig. 2). In 
patients with stage I or II rectal cancer, rates of 
disease-free survival were similar in the two 
groups, whereas in patients with stage III dis-
ease, the rate of disease-free survival was 64.9% 
in the laparoscopic-surgery group and 52.0% in 
the open-surgery group (difference, 12.9 percent-
age points; 95% CI, 2.2 to 23.6).
At 3 years after surgery, 145 patients had 
died, accounting for an overall survival rate of 
86.7% in the laparoscopic-surgery group and 
83.6% in the open-surgery group (difference, 3.1 
percentage points; 95% CI, −1.6 to 7.8) (Fig. 3). 
Overall survival rates according to disease stage 
were also similar in the two groups.
Distant metastases at 3 years after surgery 
were reported in 19.1% of the patients in the 
laparoscopic-surgery group and 22.1% of those 
in the open-surgery group, including one port-
site metastasis in the laparoscopic-surgery group 
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and one tumor recurrence in the laparotomy 
wound in the open-surgery group.
Discussion
In this trial, we compared the rates of locoregional 
recurrence of rectal cancer after laparoscopic or 
open resection. Locoregional recurrences were 
recorded in 5.0% of the patients in each of the 
two groups. In the Dutch trial of total mesorectal 
excision by Kapiteijn et al.,8 among 1805 patients 
with rectal cancer who underwent open resection, 
the locoregional recurrence rate at 2 years was 
5.3%, a rate similar to that in our study.
In the Conventional versus Laparoscopic- 
Assisted Surgery in Colorectal Cancer (CLASICC) 
trial, the first multicenter, randomized study to 
determine the effect of laparoscopic surgery on 
rectal-cancer outcomes involving 381 patients, 
the locoregional recurrence rate at 3 years was 
9.7% after laparoscopic surgery and 10.1% after 
open surgery.17 The presence of involved cir-
cumferential resection margins, which predis-
pose patients to locoregional recurrence, were 
observed in 16% of the patients after laparo-
scopic surgery in the CLASICC trial, as com-
pared with 10% of those in the laparoscopic-
surgery group in our study.18,19 Recently, in the 
Comparison of Open versus Laparoscopic Sur-
gery for Mid or Low Rectal Cancer after Neoad-
juvant Chemoradiotherapy (COREAN) study10 
involving 340 patients with cancer of the mid-
dle or lower rectum who had received preopera-
tive chemoradiotherapy, rates of locoregional 
recurrence were 2.6% after laparoscopic sur-
gery and 4.9% after open surgery. The presence 
of involved circumferential resection margins 
in the COREAN trial (2.9% after laparoscopic 
surgery and 4.1% after open surgery) were 
lower than those in our study.20 However, we 
considered circumferential resection margins 
as being involved when tumor cells were pres-
ent within 2 mm from the lateral surface of the 
mesorectum, whereas the COREAN study group 
used a 1-mm margin. The use of a 2-mm mar-
gin yields a higher rate of involved circumfer-
ential resection margins.16
In our study, laparoscopic surgery in patients 
with cancer in the lower third of the rectum was 
associated with a lower rate of involved circum-
ferential resection margin and a lower locore-
gional recurrence rate than was open surgery. 
During laparoscopic surgery, narrow spaces such 
Table 1. Clinical and Pathological Characteristics of the Patients at Baseline.*
Characteristic
Laparoscopic Surgery 
(N = 699)
Open Surgery 
(N = 345)
Sex — no. (%)
Male 448 (64) 211 (61)
Female 251 (36) 134 (39)
Age — yr 66.8±10.5 65.8±10.9
American Society of Anesthesiologists 
classification — no. (%)
I: healthy 156 (22) 65 (19)
II: mild systemic disease 386 (55) 211 (61)
III: severe systemic disease 131 (19) 61 (18)
IV: severe life-threatening systemic 
disease
5 (1) 1 (<1)
Missing data 21 (3) 7 (2)
Body-mass index† 26.1±4.5 26.5±4.7
Distance of tumor from anal verge — 
no. (%)
Upper rectum: 10 to 15 cm 223 (32) 116 (34)
Middle rectum: 5 to <10 cm 273 (39) 136 (39)
Lower rectum: <5 cm 203 (29) 93 (27)
Clinical stage — no. (%)
I 201 (29) 96 (28)
II 209 (30) 107 (31)
III 257 (37) 126 (37)
Missing data 32 (5) 16 (5)
Preoperative radiotherapy — no. (%) 412 (59) 199 (58)
Preoperative chemotherapy — no./ 
total no. (%)
196/609 (32) 99/295 (34)
No residual tumor — no./total no. 
(%)‡
33/412 (8) 19/199 (10)
Pathological stage — no. (%)§
I 231 (33) 107 (31)
II 180 (26) 91 (26)
III 233 (33) 125 (36)
IV 4 (1) 0
Missing data 18 (3) 3 (1)
Macroscopic completeness of resec-
tion — no. (%)
Complete 589 (84) 303 (88)
Partially complete 58 (8) 19 (6)
Incomplete 19 (3) 9 (3)
Missing data 33 (5) 14 (4)
Lymph nodes harvested
Median no. (IQR) 13 (10–18) 14 (10–19)
Missing data — no. (%) 16 (2) 4 (1)
* Plus–minus values are means ±SD. There were no significant differences be-
tween the groups. Percentages may not total 100 because of rounding. IQR 
denotes interquartile range.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ The denominator is the number of patients who received preoperative radio-
therapy.
§ The patients with no residual tumor were not included in the analysis of patho-
logical stage.
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Table 2. Involved Circumferential Resection Margin and Locoregional Recurrence.
Type of Lesion and Surgery
Involved Circumferential Resection 
Margin*
Locoregional Recurrence in  
Intention-to-Treat Population
Locoregional Recurrence  
in As-Treated Population
Patients with 
Finding†
Between-Group 
Difference‡ Rate
Between-Group 
Difference‡ Rate
Between-Group 
Difference‡
no./total no. (%)
percentage points
(95% CI) %
percentage points
(90 % CI) %
percentage points
(90 % CI)
All lesions
Laparoscopic surgery 56/588 (10) −0.5 (−4.9 to 3.5) 5.0 0.0 (−2.6 to 2.6) 4.3 −2.0 (−4.7 to 0.7)
Open surgery 30/300 (10) 5.0 6.3
Upper rectal lesion
Laparoscopic surgery 18/196 (9) −0.1 (−8.2 to 6.4) 3.5 0.6 (−2.9 to 4.1) 3.0 −0.9 (−4.6 to 2.8)
Open surgery 9/97 (9) 2.9 3.9
Middle rectal lesion
Laparoscopic surgery 22/228 (10) 6.2 (0.1 to 11.2) 6.5 4.1 (0.7 to 7.5) 5.7 1.6 (−2.3 to 5.5)
Open surgery 4/115 (3) 2.4 4.1
Lower rectal lesion
Laparoscopic surgery 15/164 (9) −12.4 (−23.2 to −3.0) 4.4 −7.3 (−13.9 to −0.7) 3.8 −8.9 (−15.6 to −2.2)
Open surgery 17/79 (22) 11.7 12.7
* An involved circumferential resection margin was defined as the presence of tumor cells within 2 mm of the lateral surface of the mesorec-
tum. This finding is a risk factor for locoregional recurrence (i.e., recurrence in the pelvic or perineal area).
† The denominator for the percentage calculation in this category was the number of patients without complete remission.
‡ Between-group differences were calculated by subtracting the percentage of patients with the finding in the open-surgery group from the 
percentage in the laparoscopic-surgery group.
as the lower pelvis are better visualized than in 
open surgery owing to the use of a laparoscope, 
which projects a magnified and well-illuminated 
image of the operative field on the monitors. A 
clear view is of paramount importance to accom-
plish a resection of the cancer with sufficient 
margins. As a result of tapering of the mesorec-
tum at the level of the pelvic floor, tissue mar-
gins around low rectal cancers are smaller than 
those around tumors located in the middle or 
upper rectum, which predisposes such tumors 
to incomplete radical resection.21 Therefore, a 
procedure called extralevatory abdominoperineal 
rectum extirpation (ELAPE), in which a part of 
the pelvic floor musculature is resected through 
a perineal approach, has been introduced. Dur-
ing the past decade, the ELAPE principle was 
introduced but was not included in the COLOR 
II study protocol.22 However, the debate on the 
value of this technique continues.
The disease-free survival rates at 3 years in 
our study were 74.8% after laparoscopic surgery 
and 70.8% after open surgery, as compared with 
rates of 79.2% and 72.5%, respectively, during 
the same follow-up period in the COREAN 
study.10 In our study, among patients with stage 
III disease, disease-free survival rates were 64.9% 
after laparoscopic surgery and 52.0% after open 
surgery. A similar finding was reported by Lacy 
and colleagues15 among patients who underwent 
laparoscopic resection of lymph-node–positive 
colon cancers. These observations may confirm 
the experimental findings that less surgical 
trauma associated with the use of laparoscopic 
techniques reduces tumor recurrence.23 In a 
study involving patients undergoing laparo-
scopic and open colonic resection, laparoscopic 
surgery was followed by attenuated stress re-
sponses and improved preservation of immune 
function.24 Further studies are necessary to deter-
mine whether laparoscopic surgery for cancer is 
associated with improved survival.
The size of the cohort in our study allowed 
for the use of a noninferiority margin of 5 per-
centage points, whereas in the smaller COREAN 
trial, the noninferiority margin was 15 percent-
age points.20 Since centers in eight countries in 
Europe, North America, and Asia participated in 
our study, the outcomes appear to be applicable 
to surgical practice in general.
Rectal-cancer surgery, regardless of which 
technique is used, is technically demanding and 
requires sufficient training to be performed 
safely. We verified the surgical quality of laparo-
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scopic total mesorectal excision by reviewing 
unedited recordings of five consecutive laparo-
scopic procedures for each center. Laparoscopic 
surgical expertise is difficult to measure objec-
tively but is reflected to a certain extent by 
operative time and conversion rate.25 The medi-
an operating times for laparoscopic procedures 
were 240 minutes in our study and 245 minutes 
in the COREAN trial; the latter obviously was 
recorded by highly skilled surgeons, given the 
low conversion rate of only 1% in that study.20 
The conversion rate in our study remained 16% 
throughout the study period, whereas a decline 
in the conversion rate from 38% in the first year 
to 16% in the last year of the trial was reported 
by the CLASICC group.19
In our study, patients with T4 and T3 lesions 
within 2 mm of the endopelvic fascia were ex-
cluded because laparoscopic resection of these 
large tumors is very difficult and could result in 
less-than-complete resection with subsequent 
higher rates of locoregional recurrence. There-
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Figure 2. Disease-free Survival, According to Disease Stage.
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Figure 3. Overall Survival, According to Disease Stage.
fore, we do not recommend laparoscopic surgery 
in patients with T4 or T3 rectal cancers with 
threatened circumferential margins.
A limitation of our study is the absence of 
centralized macroscopic and microscopic evalu-
ation of the resected specimens. However, all 
pathologists adhered to a detailed standardized 
protocol. Another limitation is the use of dif-
ferent imaging methods to determine the loca-
tion of the tumor. It would have been preferable 
to standardize the imaging technique of the 
pelvis and calibrate the measurements centrally 
by independent professionals.
Some surgeons insert one of their hands 
through a gastight port in the abdomen during 
laparoscopic colorectal surgery to allow for 
manual retraction of tissues and tactile feed-
back, a procedure called hand-assisted laparo-
scopic surgery.26 The group who designed the 
study thought that a hand would obstruct the 
laparoscopic view of the narrow pelvis, so this 
technique was not part of the current protocol.
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In conclusion, long-term outcomes of the 
COLOR II trial indicate that laparoscopic sur-
gery is as safe and effective as open surgery in 
patients with rectal cancers without invasion of 
adjacent tissues.
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